

Primary macronodular adrenal hyperplasia

Description

Primary macronodular adrenal hyperplasia (PMAH) is a disorder characterized by multiple lumps (nodules) in the adrenal glands, which are small hormone-producing glands located on top of each kidney. These nodules, which usually are found in both adrenal glands (bilateral) and vary in size, cause adrenal gland enlargement (hyperplasia) and result in the production of higher-than-normal levels of the hormone cortisol. Cortisol is an important hormone that suppresses inflammation and protects the body from physical stress such as infection or trauma through several mechanisms including raising levels of blood glucose, also called blood sugar.

PMAH typically becomes evident in a person's forties or fifties. It is considered a form of Cushing syndrome, which is characterized by increased levels of cortisol resulting from one of many possible causes. These increased cortisol levels lead to weight gain in the face and upper body, fragile skin, bone loss, fatigue, and other health problems. However, some people with PMAH do not experience these signs and symptoms and are said to have subclinical Cushing syndrome.

Frequency

PMAH is a rare disorder. It is present in less than 1 percent of cases of endogenous Cushing syndrome, which describes forms of Cushing syndrome caused by factors internal to the body rather than by external factors such as long-term use of certain medicines called corticosteroids. The prevalence of endogenous Cushing syndrome is about 1 in 26,000 people.

Causes

In about half of individuals with PMAH, the condition is caused by mutations in the *ARMC5* gene. This gene provides instructions for making a protein that is thought to act as a tumor suppressor, which means that it helps to prevent cells from growing and dividing too rapidly or in an uncontrolled way. *ARMC5* gene mutations are believed to impair the protein's tumor-suppressor function, which allows the overgrowth of certain cells. It is unclear why this overgrowth is limited to the formation of adrenal gland nodules in people with PMAH.

PMAH can also be caused by mutations in the GNAS gene. This gene provides

instructions for making one component, the stimulatory alpha subunit, of a protein complex called a guanine nucleotide-binding protein (G protein). The G protein produced from the *GNAS* gene helps stimulate the activity of an enzyme called adenylate cyclase. This enzyme is involved in controlling the production of several hormones that help regulate the activity of certain endocrine glands, including the adrenal glands. The *GNAS* gene mutations that cause PMAH are believed to result in an overactive G protein. Research suggests that the overactive G protein may increase levels of adenylate cyclase and result in the overproduction of another compound called cyclic AMP (cAMP). An excess of cAMP may trigger abnormal cell growth and lead to the adrenal nodules characteristic of PMAH.

Mutations in other genes, some of which are unknown, can also cause PMAH.

Learn more about the genes associated with Primary macronodular adrenal hyperplasia

- APC
- ARMC5
- FH
- GNAS
- MC2R
- MEN1

Additional Information from NCBI Gene:

PDE11A

Inheritance

People with PMAH caused by *ARMC5* gene mutations inherit one copy of the mutated gene in each cell. The inheritance is considered autosomal dominant because one copy of the mutated gene is sufficient to make an individual susceptible to PMAH. However, the condition develops only when affected individuals acquire another mutation in the other copy of the *ARMC5* gene in certain cells of the adrenal glands. This second mutation is described as somatic. Instead of being passed from parent to child, somatic mutations are acquired during a person's lifetime and are present only in certain cells. Because somatic mutations are also required for PMAH to occur, some people who have inherited the altered *ARMC5* gene never develop the condition, a situation known as reduced penetrance.

When PMAH is caused by *GNAS* gene mutations, the condition is not inherited. The *GNAS* gene mutations that cause PMAH are somatic mutations. In PMAH, the gene mutation is believed to occur early in embryonic development. Cells with the mutated *GNAS* gene can be found in both adrenal glands.

Other Names for This Condition

- ACTH-independent macronodular adrenal hyperplasia
- ACTH-independent macronodular adrenocortical hyperplasia
- Adrenal Cushing syndrome due to AIMAH
- Adrenocorticotropic hormone-independent macronodular adrenal hyperplasia
- AIMAH
- Corticotropin-independent macronodular adrenal hyperplasia
- PMAH
- Primary bilateral macronodular adrenal hyperplasia

Additional Information & Resources

Genetic Testing Information

 Genetic Testing Registry: Acth-independent macronodular adrenal hyperplasia 2 (ht tps://www.ncbi.nlm.nih.gov/gtr/conditions/C4014803/)

Genetic and Rare Diseases Information Center

 Cushing syndrome due to macronodular adrenal hyperplasia (https://rarediseases.i nfo.nih.gov/diseases/10824/index)

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD) (https://rarediseases.org/)

Clinical Trials

 ClinicalTrials.gov (https://clinicaltrials.gov/search?cond=%22Primary macronodular adrenal hyperplasia%22)

Catalog of Genes and Diseases from OMIM

- ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 1; AIMAH1 (https://omim.org/entry/219080)
- ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 2; AIMAH2 (https://omim.org/entry/615954)

Scientific Articles on PubMed

PubMed (https://pubmed.ncbi.nlm.nih.gov/?term=%28macronodular+adrenal+hyper plasia%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D)

References

- Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet P, Bourdeau I, Zerbini MC, Pereira MA, Gomes GC, Rocha Mde S, Chambo JL, Lacroix A, Mendonca BB, Fragoso MC. ARMC5 mutations are a frequent cause of primarymacronodular adrenal Hyperplasia. J Clin Endocrinol Metab. 2014Aug;99(8): E1501-9. doi: 10.1210/jc.2013-4237. Epub 2014 Apr 7. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/24708098)
- Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F, Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations inmacronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med. 2013 Nov28;369(22):2105-14. doi: 10.1056/NEJMoa1304603. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/24283224) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727443/)
- De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateralmacronodular adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2014Jun;21(3):177-84. doi: 10.1097/MED.000000000000061. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/24739311)
- Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf C, Konig K, Arlt W, Buttner R, May P, Allolio B, Schneider JG. Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germlineand somatic mutations are associated with both primary macronodular adrenalhyperplasia and meningioma. J Clin Endocrinol Metab. 2015 Jan;100(1): E119-28.doi: 10.1210/jc.2014-2648. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/25279498) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283009/)
- Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A,Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA. Macronodular adrenal hyperplasia due to mutations in an armadillo repeatcontaining 5 (ARMC5) gene: a clinical and genetic investigation. J ClinEndocrinol Metab. 2014 Jun;99(6):E1113-9. doi: 10.1210/jc.2013-4280. Epub 2014Mar 6. Citation on PubMed (https://pubmed.ncbi.nlm.nih.gov/24601692) or Free article on PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037724/)
- Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC, LuconAM, Mendonca BB. Cushing's syndrome secondary to adrenocorticotropin-independentmacronodular adrenocortical hyperplasia due to activating mutations of GNAS1gene. J Clin Endocrinol Metab. 2003 May;88(5):2147-51. doi:10.1210/jc.2002-021362. Citation on PubMed (https://pubmed.ncbi.nlm.nih.g ov/12727968)

 Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C,Oftedal BE, Cutfield R, Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB,Torpy DJ, Scott HS. ARMC5 mutations are common in familial bilateral macronodularadrenal hyperplasia. J Clin Endocrinol Metab. 2014 Sep;99(9):E1784-92. doi:10.1210/jc.2014-1265. Epub 2014 Jun 6. Citation on PubMed (https://pubme d.ncbi.nlm.nih.gov/24905064)

Last updated May 1, 2015